Stay updated on market trends for ZLDPF. Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names The $200B GLP-1 market ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

The EU pharma deal worth up to $5.3B to develop Zealand’s (OTCPK:ZLDPF) weight loss candidate petrelintide is the newest partnership to enter the obesity drug market, expected to generate as ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vicarious Surgical (RBOT – Research Report), Alkermes (ALKS ...

Shares of ZLDPF stock opened at $97.78 on Thursday. The company has a market cap of $6.94 billion, a PE ratio of -41.43 and a beta of 0.88. The company has a current ratio of 35.49, a quick ratio ...

Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...

Zealand Pharma AS (ZLDPF) reported significant clinical advancements in their obesity pipeline, particularly with petrelintide and survodutide. The company has a strong cash position of DKK9 billion, ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF).

Shares of weight loss drug developers gained on Wednesday after Roche (OTCQX:RHHBF) announced a multi-billion-dollar deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF) to jointly develop an ...